Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.71 |
| ▸ | CDK1 | P06493 | 7/20 | 0.71 |
| ▸ | KDR | P35968 | 4/20 | 0.71 |
| ▸ | IGF1R | P08069 | 5/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.59 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580117 | 0.85 | CDK1 (0.52) | CDK2CDK1KDRIGF1RGSK3B | |
| SCHEMBL3938954 | 0.83 | CDK1 (1.00) | CDK2CDK1KDRIGF1RGSK3B | |
| SCHEMBL4459525 | 0.82 | IGF1R (1.00) | CDK2CDK1KDRIGF1RGSK3B | |
| SCHEMBL4578774 | 0.81 | CDK1 (0.74) | CDK2CDK1KDRCCNB1CCNE1 | |
| SCHEMBL5258869 | 0.80 | CDK1 (0.77) | CDK2CDK1KDRIGF1RGSK3B | |
| SCHEMBL5259656 | 0.80 | CDK1 (0.76) | CDK2CDK1KDRIGF1RGSK3B | |
| SCHEMBL14367833 | 0.80 | IGF1R (0.68) | CDK2CDK1KDRIGF1RGSK3B | |
| SCHEMBL4578234 | 0.79 | KDR (0.74) | CDK2CDK1KDR | |
| SCHEMBL5261726 | 0.78 | IGF1R (0.85) | CDK2CDK1KDRIGF1RGSK3B | |
| SCHEMBL12726459 | 0.77 | CDK1 (0.65) | CDK2CDK1KDRIGF1RGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456191-B2 | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-11-25 | — | — | US | disclosed |
| US-7456191-B2 | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-11-25 | — | — | US | disclosed |
| US-7456191-B2 | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-11-25 | — | — | US | disclosed |
| EP-1861378-A1 | N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| WO-2006099974-A1 | N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | CDK2, FLT1, CDK4 | CDK2 1/4885CDK1 6/4885KDR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.